Reconstitution with Bcr-Abl negative recipient haematopoiesis after allogeneic BMT for CML

被引：0
作者：
Serrano, J [1 ]
Román, J [1 ]
Castillejo, JA [1 ]
Navarro, JA [1 ]
Pascual, A [1 ]
García-Rubio, I [1 ]
Falcón, M [1 ]
Martín, C [1 ]
Sánchez, J [1 ]
Herrera, C [1 ]
Torres, A [1 ]
机构：
[1] Reina Sofia Hosp, Dept Haematol, Cordoba, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1998年 / 102卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：318 / 318
页数：1
相关论文
共 50 条
  • [21] BCR-ABL transcript levels and BCR-ABL/BCR transcript ratios in CML patients with good or bad response to treatment.
    Moravcová, J
    Regner, J
    Brezinová, J
    Klamová, H
    BLOOD, 2001, 98 (11) : 264B - 264B
  • [22] Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs
    Iraci, Nunzio
    Valli, Emanuele
    Gherardi, Samuele
    Soverini, Simona
    Kalebic, Thea
    Baccarani, Michele
    Martinelli, Giovanni
    Perini, Giovanni
    BLOOD, 2009, 114 (22) : 351 - 351
  • [23] Bcr-Abl kinase inhibition as the basis of therapy for CML
    Druker, BJ
    Talpaz, M
    Resta, D
    Peng, B
    Buchdunger, E
    Ford, J
    Sawyers, CL
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 130 - 130
  • [24] Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
    Jabbour, Elias
    Saglio, Giuseppe
    Radich, Jerald
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04) : 223 - 229
  • [25] CHARACTERIZATION OF RECIPROCAL BCR-ABL BREAKPOINTS IN CML BY PCR
    ZHANG, JG
    CROSS, NCP
    MELO, JV
    GOLDMAN, JM
    EXPERIMENTAL HEMATOLOGY, 1993, 21 (08) : 1091 - 1091
  • [26] Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia
    Ralph B Arlinghaus
    Oncogene, 2002, 21 : 8560 - 8567
  • [27] Allogeneic transplant for myelofibrosis, CMML and Philadelphia (Ph) chromosome negative/BCR-ABL negative CML (atypical CML): Potential survival advantage with reduced intensity regimens.
    Mittal, P
    Saliba, RM
    Giralt, SA
    Shahjahan, M
    Cohen, AI
    Karandish, S
    Champlin, RE
    De Lima, M
    BLOOD, 2002, 100 (11) : 428A - 428A
  • [28] Association of BCR-ABL mutation testing in patients with CML with likelihood of improvement in subsequent BCR-ABL test results.
    Smyth, Carol
    Bhan, Jason M.
    Dhaliwal, Ajitpal Singh
    Sorokina, Tatiana
    Parikh, Niyati
    Levitz, Jason S.
    Radich, Jerald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Long-term lymphoid-restricted split chimerism after myeloablative allogeneic BMT for bcr-abl plus ALL
    Spyridonidis, A.
    Bertz, H.
    Waterhouse, M.
    Finke, J.
    BONE MARROW TRANSPLANTATION, 2008, 42 (12) : 829 - 831
  • [30] DETECTION OF RESIDUAL DISEASE AFTER BMT FOR CML BY AMPLIFICATION OF THE BCR-ABL BREAKPOINT FROM GENOMIC DNA - COMPARISON WITH RT-PCR
    ZHANG, JG
    LIN, F
    CROSS, NCP
    GOLDMAN, JM
    BLOOD, 1994, 84 (10) : A496 - A496
12345